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A B S T R A C T
Positron emission tomography (PET) using fluorodeoxyglucose (18F) (FDG) is in-
creasingly used in the staging of lymphoma. Results of the use of PET during and 
after completion of therapy for staging of Hodgkin’s lymphoma and aggressive non-
Hodgkin’s lymphoma demonstrate a highly predictive value for outcome. Based on 
recommendations of the International Harmonization Project, FDG-PET has been 
incorporated into the revised response criteria of lymphoma. There is currently no 
evidence to support the use of FDG-PET in indolent lymphoma, nor for its routine 
use during follow-up. Evidence also lacks on the impact of FDG-PET on treatment 
outcome. Clearly, well designed clinical trials are warranted to determine the subsets 
of patients who will benefit from this modality.
I N T R O D U C T I O N
Positron emission tomography (PET) using fluorodeoxyglucose (FDG), a glucose 
analog, with the positron-emitting radioactive isotope fluorine-18 substituted for 
the normal hydroxyl group at the 2’ position in the glucose molecule, is a functional 
imaging technique that is widely used in the management of patients with lymphoma. 
FDG-PET is based on the principle that malignant cells have increased rates of glucose 
uptake and metabolism compared with normal tissues. There has been considerable 
progress in investigating the value of FDG-PET in lymphoma since the first report 
back in 1987,1 but its precise role in disease management has not been well defined 
because it has been introduced into clinical practice without well designed prospective 
randomized trials. In lymphomas, FDG-PET imaging has been evaluated in all the 
time points of management. In this article we will review from a clinical point of inter-
est, the evidence for the use of FDG-PET in monitoring the treatment of lymphoma, 
including initial staging, interim and post-treatment response evaluation, follow-up, 
and finally the issue of response-adapted therapy.
F D G - P E T  I N  I N I T I A l  S T A G I N G  O F  l y m P h O m A
Staging of lymphoma is usually performed using computed tomography (CT). 
However, CT lacks functional information, which can impede the identification of 
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AbbreviAtions
ASCT = autologous stem cell 
transplantation
CR = complete remission
CRu = complete remission unconfirmed
CT = computed tomography
DLBCL = diffuse large B-cell lymphoma
FDG = fluorodeoxyglucose (18F)
HL = Hodgkin’s lymphoma
PET = positron emission tomography
PFS = progression-free survival
PR = partial response
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disease in normal-sized tissue. FDG-PET has become an 
established imaging modality to stage lymphoma and over 
the past decade its reliability has dramatically improved, with 
technological advances including three-dimensional acquisi-
tion, and image fusion between PET and CT. Integration of 
both modalities may outperform both FDG-PET alone and 
CT alone in staging of malignant lymphoma.
Clinical staging of both Hodgkin’s lymphoma (HL) and 
non-Hodgkin’s lymphoma is critical for determining the treat-
ment strategy and prognosis. The Ann Arbor staging system 
is used for staging, initially traditionally based on physical 
examination and bone marrow evaluation, but subsequently 
CT scans have been incorporated.2 It is questionable whether 
PET should be incorporated into the Ann Arbor staging sys-
tem. PET is highly sensitive in detecting nodal and extranodal 
involvement by most histological subtypes of lymphoma and 
may provide complementary information to conventional 
staging methods.3
Lymphomas differ with regard to their glucose metabolic 
activity. Systemic studies show that indolent lymphomas ex-
hibit lower glucose metabolic activity (FDG uptake) than 
more aggressive lymphomas.4 Most types of lymphoma are 
FDG-avid with a sensitivity that exceeds 80% and a specificity 
of about 90%, which is superior to CT.5 Positron emission 
tomography and CT are 80% to 90% concordant in staging of 
patients who have diffuse large B-cell lymphoma (DLBCL), 
follicular lymphoma, and mantle cell lymphoma. In patients 
with discordant results, PET results in upstaging due to 
detection of additional nodal, hepatic, or splenic disease. In 
contrast, concordance of PET and CT in determining clinical 
stage occurs in only 60% to 80% of patients with HL, with 
comparable discordant findings in both directions.6 A meta-
analysis of FDG-PET in staging of lymphoma demonstrated 
a pooled sensitivity for 14 studies of 90.9% (95% CI, 88.0 to 
93.4) with a false-positive rate of 10.3% (95% CI, 7.4 to 13.8) 
with an apparently higher sensitivity and false-positive rate 
in patients who had HL.7 Although PET can detect bone or 
bone marrow involvement, PET alone is unreliable in detect-
ing limited bone marrow involvement and cannot substitute 
for bone marrow biopsy in lymphoma staging.8
The revised guidelines for the staging and the response 
criteria of HL and non-Hodgkin’s lymphoma were recently 
published to include the expanding role of PET/CT. The two 
major summary points of the International Harmonization 
Project were the standardization of performance and inter-
pretation of PET in lymphoma9 and new response criteria 
incorporating PET and bone marrow immunohistochemistry.10 
One important outcome of the Project was the elimination 
of the term complete remission unconfirmed (CRu) that 
provides a better separation of the progression-free survival 
(PFS) curves between complete remission (CR) and partial 
response (PR) patients. Despite the superior sensitivity and 
specificity compared with CT, PET is currently not required 
as part of standard lymphoma staging, although the expert 
panel recommends pretreatment PET in patients with HL or 
DLBCL enrolled in a clinical trial. The reasons for not being 
incorporated in standard staging of lymphoma are the cost, 
the small percentage of patients (15% to 20%) in whom PET 
detects additional disease sites that modify clinical stage, 
and more importantly the even fewer patients for whom this 
modification alters management and outcome. The lack of 
evidence to suggest an impact of initial FDG-PET staging and 
modified disease management on patient outcome remains 
a crucial issue that needs to be addressed in well designed 
prospective trials. The expert panel also does not recommend 
the use of PET in initial staging of the routinely FDG-avid 
follicular and mantle cell lymphomas and the variably FDG-
avid other indolent and aggressive lymphomas, unless patients 
are participating in a clinical trial and overall response rate 
/complete remission is a primary study end point.
F D G - P E T  I N  I N T E R I m  R E S P O N S E 
E v A l U A T I O N  O F  l y m P h O m A
Conventional methods for treatment response monitor-
ing are based on morphological criteria, and a reduction 
in tumor size on CT as the most important determinant. 
However, the rate of tumor regression may not be an accurate 
predictor of outcome. Functional imaging with FDG-PET 
enables evaluation of early metabolic changes rather than 
morphological changes. A considerable number of studies 
of FDG-PET after 1-3 cycles of chemotherapy for aggressive 
non-Hodgkin’s lymphoma11-14 and HL15,16 demonstrate that 
early metabolic changes are highly predictive of treatment 
response and outcome.
In a large retrospectively studied cohort of 121 patients 
with high-grade non-Hodgkin’s lymphoma, the response on 
FDG-PET following 2 or 3 cycles of treatment was highly 
predictive of PFS and overall survival.17 The estimated 5-year 
PFS rate was 89% for patients with PET-negative results, 59% 
for patients with minimal residual FDG uptake, and 16% 
for patients with PET-positive results. Interim FDG-PET 
has also been compared with the International Prognostic 
Index (IPI), a score that is currently used to prognosticate 
lymphoma. In a multivariate analysis, interim FDG-PET was 
more predictive than the IPI for PFS (P <0.058) and overall 
survival (P <0.03).12
Interim PET after 2 or 3 cycles of ABVD chemotherapy 
has also a highly predictive value in HL, with 5-year PFS rates 
of 39% for patients with PET-positive results and 92% for 
patients with PET-negative results.18 A study including only 
patients with advanced stage HL and scanned after 2 cycles of 
ABVD found 2-year PFS rates of 0% for patients with early 
PET-positive results and 94% for patients with PET-negative 
results.19 Concerns have been recently raised regarding the 
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positive predictive value of interim PET in patients treated 
with the more dose-intense BEACOPPesc regimen.20 Al-
though several studies demonstrate a highly predictive value, 
the expert panel of the International Harmonization Project 
does not recommend interim PET in routine clinical prac-
tice. Currently there are no available data to demonstrate 
improvement in results by altering treatment based on this 
information, and interim PET is recommended in patients 
enrolled in clinical trials.
I N T E R I m  P E T  R E S P O N S E - A D A P T E D 
T h E R A P y
Currently ongoing clinical trials are addressing the issue 
of treatment modification based on the result of interim PET. 
The hypothesis tested in these trials is that some patients 
may benefit from the recognition of treatment failure early 
during first line treatment and from initiation of more ag-
gressive second line treatment as soon as possible. Trials 
are investigating whether patients with interim PET-positive 
scans for DLBCL will benefit from early modification to a 
more intensive regimen or high dose therapy and autologous 
stem cell transplantation (ASCT).21,22 Ongoing trials are also 
assessing the value of interim PET in HL. A large number 
of patients with early stage HL are overtreated, and efforts 
are focusing on identifying those who will benefit from less 
intensive therapy, reducing the long-term risk of secondary 
cancers and cardiopulmonary disease. The U.K. RAPID trial 
and the GHLSG HD16 trial are evaluating the effect of omit-
ting radiotherapy in patients with early stage HL and interim 
PET-negative results.23 Several trials are also evaluating early 
treatment intensification with BEACOPPesc or even ASCT 
in patients with advanced stage HL and a PET-positive result 
after 2 cycles of ABVD.24,25
P O S T - T R E A T m E N T  P E T  F O R  R E S P O N S E 
E v A l U A T I O N  I N  l y m P h O m A
A number of studies have demonstrated that FDG-PET 
performed after treatment is highly predictive of PFS and 
overall survival in HL and aggressive non-Hodgkin’s lympho-
mas.26-28 FDG-PET demonstrates the ability, at least to some 
extent, to distinguish between viable disease and necrosis or 
fibrotic tissue in residual masses following treatment. These 
observations led to the development of new recommenda-
tions for response criteria, incorporating FDG-PET into 
the definitions of end-of-treatment responses for FDG-avid 
lymphomas.10 Based on the recommendations of the expert 
panel of the International Harmonization Project patients 
with the routinely FDG avid HL and DLBCL should have 
a FDG-PET performed for response assessment following 
completion of treatment. A negative FDG-PET scan does 
not exclude the presence of undetectable disease, but overall 
with the new response criteria one expects the false-negative 
results will be much fewer than the false-positive, with a overall 
benefit and sparing a considerable number of patients from 
unnecessary treatment.
P E T  F O R  F O l l O w - U P  O F  l y m P h O m A
There are limited studies evaluating the role of PET during 
follow-up. A large retrospective study evaluated 151 patients 
with mediastinal lymphoma (HL and aggressive non-Hodg-
kin’s lymphoma) with follow-up PET every 6 months for the 
first 2 years and then every 12 months for a further 3 years.29 
A positive surveillance PET was documented in 30 patients 
at a median of 22 months following treatment completion. A 
biopsy was performed in all cases, confirming recurrence of 
the original disease in 17 (57%) cases, while a benign condi-
tion (fibrosis [n=9] or sarcoid-like granulomatosis [n=3]) and 
a case of thymoma were documented in the remaining 13 
(43%) cases. Although early detection of disease relapse and 
early salvage therapy in a minimal disease status is desirable, 
further prospective studies are warranted to evaluate if there 
is a role of surveillance PET in the follow-up of patients with 
lymphoma.
P E T  B E F O R E  h I G h - D O S E  S A l v A G E 
T h E R A P y  I N  l y m P h O m A
PET is also predictive of outcome following high-dose 
therapy and autologous stem cell transplantation (ASCT) 
for relapsed lymphoma. Several studies have shown that PET 
performed following induction therapy and prior to ASCT is 
highly predictive of outcome. In a large retrospective study 
of 60 patients, 30 had a negative PET before ASCT; 25 of 
those patients remained in remission and only three patients 
had disease progression following ASCT.30 Persistent abnor-
mal PET was documented in 30 patients, and 26 of those 
developed disease progression. The predictive value of PET 
in this setting was superior to that of conventional staging 
and the International Prognostic Index for non-Hodgkin’s 
lymphoma.31 However, these studies also demonstrated that 
there is a high rate of false-positive results in this setting, 
disproportionate to that seen when FDG-PET is performed 
early during first-line therapy.
I S S U E S  w I T h  P E T  I N  l y m P h O m A
There are some important limitations in the use of FDG-
PET, and these issues need to be resolved in future studies. 
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The differences in equipment, techniques, and variability in 
interpretation between readers limit the value of comparisons 
among studies. New technology such as PET/CT also limits 
comparisons with older data. Histologic subtypes of lympho-
mas also differ with regard to their glucose metabolic activity, 
with implications for both staging of disease and treatment 
monitoring.4 False-positive FDG uptake is also an important 
variable that must be taken into account when interpreting 
results. Nonmalignant conditions such as inflammation, infec-
tion, and granulomatosis (sarcoidosis or sarcoid-like lesions) 
and physiologic FDG uptake such as brown fat tissue, activated 
muscle, and hyperplasia of thymus can lead to false-positive 
results.32 Abnormal FDG uptake can also be observed in the 
bone marrow and the spleen following chemotherapy or in 
patients receiving granulocyte colony-stimulating factor (G-
CSF) after chemotherapy.33
C O N C l U S I O N
The integration of PET in the revised clinical staging 
guidelines and the elimination of CRu represents progress in 
the staging and management of patients with lymphoma. One 
must emphasize that PET does by no means replace the need 
for biopsy. PET response-adapted therapy is experimental and 
is the subject of ongoing appropriately designed clinical trials. 
There are still limitations in the guidelines of the International 
Harmonization Project that need to be addressed through 
prospective trials.
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